<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553692</url>
  </required_header>
  <id_info>
    <org_study_id>IGM-8444-001</org_study_id>
    <nct_id>NCT04553692</nct_id>
  </id_info>
  <brief_title>Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers</brief_title>
  <official_title>An Open-label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IGM Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IGM Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, Phase 1, multicenter, open-label study to determine the&#xD;
      safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination in&#xD;
      subjects with relapsed and/or refractory solid cancers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled in two stages: a dose-escalation stage and an expansion stage.&#xD;
&#xD;
      The escalation stage will investigate single agent IGM-8444 in patients with solid tumors,&#xD;
      IGM-8444 in combination with FOLFIRI for colorectal carcinoma patients, IGM-8444 in&#xD;
      combination with birinapant in patients with solid tumors, and IGM-8444 in combination with&#xD;
      venetoclax in patients with CLL/SLL. The IGM-8444 single agent expansion cohort will enroll&#xD;
      solid tumor patients and may include relapsed/refractory non-Hodgkin lymphoma patients. The&#xD;
      IGM-8444 + FOLFIRI with or without bevacizumab combination expansion cohorts will enroll&#xD;
      colorectal carcinoma patients. The IGM-8444 + birinapant combination expansion cohort will&#xD;
      enroll solid tumor patients, IGM-8444 in combination with venetoclax will enroll patients&#xD;
      with CLL/SLL.&#xD;
&#xD;
      IGM-8444 will be administered intravenously (IV).&#xD;
&#xD;
      An alternative dosing schedule may be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events of IGM-8444 as a single agent as single agent and in combination with FOLFIRI +/- bevacizumab, IGM-8444 in combination with birinapant, and IGM-8444 in combination with venetoclax</measure>
    <time_frame>From Cycle 1 Day 1 through 28 days after the final dose of study drug</time_frame>
    <description>Incidence of treatment-related AEs graded according to the NCI Common Technology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) of IGM-8444 as a single agent as single agent and in combination with FOLFIRI +/- bevacizumab, IGM-8444 in combination with birinapant, and IGM-8444 in combination with venetoclax</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number and proportion of patients experiencing at least one DLT will be used as the primary measure to evaluate the RP2D of IGM-8444</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of IGM-8444</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through end of treatment at approximately 6 months</time_frame>
    <description>Area Under the Curve (AUC) of IGM-8444 as a single agent and in combination with FOLFIRI +/- bevacizumab, IGM-8444 in combination with birinapant, and IGM-8444 in combination with venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of IGM-8444</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through end of treatment at approximately 6 months</time_frame>
    <description>Clearance (CL) of IGM-8444 as a single agent and in combination with FOLFIRI +/- bevacizumab, IGM-8444 in combination with birinapant, and IGM-8444 in combination with venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V) of IGM-8444</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through end of treatment at approximately 6 months</time_frame>
    <description>Volume of distribution (V) of IGM-8444 as a single agent and in combination with FOLFIRI +/- bevacizumab, IGM-8444 in combination with birinapant, and IGM-8444 in combination with venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>through end of treatment at approximately 6 months</time_frame>
    <description>Immunogenicity as assessed by detection of anti-drug antibodies (ADAs) to IGM-8444</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Study duration of approximately 36 months</time_frame>
    <description>Preliminary efficacy of objective response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Study duration of approximately 36 months</time_frame>
    <description>Preliminary efficacy of duration of response (DoR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Study duration of approximately 36 months</time_frame>
    <description>Preliminary efficacy of progression-free survival (PFS)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>IGM-8444 Single Agent Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously as a single agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 Single Agent Alternate Dosing Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + FOLFIRI Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with FOLFIRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 Single Agent Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously as a single agent in disease specific cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + FOLFIRI Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with FOLFIRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with FOLFIRI and bevacizumab (and approved biosimilars).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + Birinapant Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + Birinapant Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + Venetoclax Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with Venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGM-8444 + Venetoclax Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGM-8444 will be administered intravenously in combination with Venetoclax.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGM-8444</intervention_name>
    <description>DR5 Agonist Investigational Drug</description>
    <arm_group_label>IGM-8444 + Birinapant Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + Birinapant Expansion</arm_group_label>
    <arm_group_label>IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion</arm_group_label>
    <arm_group_label>IGM-8444 + FOLFIRI Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + FOLFIRI Expansion</arm_group_label>
    <arm_group_label>IGM-8444 + Venetoclax Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + Venetoclax Expansion</arm_group_label>
    <arm_group_label>IGM-8444 Single Agent Alternate Dosing Escalation</arm_group_label>
    <arm_group_label>IGM-8444 Single Agent Escalation</arm_group_label>
    <arm_group_label>IGM-8444 Single Agent Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Chemotherapy Regimen</description>
    <arm_group_label>IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion</arm_group_label>
    <arm_group_label>IGM-8444 + FOLFIRI Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + FOLFIRI Expansion</arm_group_label>
    <other_name>Fluorouracil or 5-FU</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (and approved biosimilars)</intervention_name>
    <description>Targeted Therapy</description>
    <arm_group_label>IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Birinapant</intervention_name>
    <description>SMAC-mimetic Investigational Drug</description>
    <arm_group_label>IGM-8444 + Birinapant Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + Birinapant Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Targeted Therapy</description>
    <arm_group_label>IGM-8444 + Venetoclax Escalation</arm_group_label>
    <arm_group_label>IGM-8444 + Venetoclax Expansion</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years at time of signing Informed Consent Form&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Patients who are either refractory to or intolerant of existing standard therapy or&#xD;
             for whom no effective further standard of care therapy exists.&#xD;
&#xD;
          -  No more than three prior therapeutic regimens (&quot;therapeutic&quot; is defined as any&#xD;
             cytotoxic, biologic, or targeted therapy [approved or investigational] with intent to&#xD;
             treat the cancer) administered for the treatment of cancer in the advanced/metastatic&#xD;
             setting.&#xD;
&#xD;
          -  For dose escalation cohorts only: Patients with either measurable or evaluable&#xD;
             disease.&#xD;
&#xD;
          -  Patients with histologic documentation of incurable, locally advanced or metastatic&#xD;
             prostate cancer with non-measurable disease are eligible if they have an increase in&#xD;
             prostate-specific antigen (PSA) level of &gt; 50% from current level, the absolute&#xD;
             increase is ≥ 5 ng/mL, and the increase is confirmed a second time.&#xD;
&#xD;
          -  Patients with histologic documentation of incurable, locally advanced or metastatic&#xD;
             ovarian cancer with non-measurable disease are eligible if they have an increase of &gt;&#xD;
             2 × the baseline level in CA-125 (or &gt; 2 × the ULN in case of prior normal CA-125&#xD;
             level) and the increase is confirmed a second time.&#xD;
&#xD;
          -  Adequate organ function as evidenced by (hematologic parameters must be assessed at&#xD;
             least 14 days from the last growth factor support or prior transfusion, if any):&#xD;
&#xD;
               -  ANC ≥ 1000/μL.&#xD;
&#xD;
               -  Total hemoglobin ≥ 9 g/dL.&#xD;
&#xD;
               -  Platelet count ≥ 100,000/μL.&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or estimated creatinine&#xD;
                  clearance ≥ 50 mL/min (Cockcroft Gault or other institutional methods).&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) and serum ALT ≤ 2 × ULN.&#xD;
&#xD;
                    -  AST and ALT ≤ 3 × ULN is allowed if liver function abnormalities are due to&#xD;
                       underlying malignancy.&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 × ULN regardless of liver involvement secondary to&#xD;
                  tumor.&#xD;
&#xD;
                    -  Inclusion of patients with increased serum indirect bilirubin (≤ 3 × ULN)&#xD;
                       due to Gilbert's syndrome is permitted.&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 × the ULN&#xD;
&#xD;
               -  Albumin ≥3.0 g/dL.&#xD;
&#xD;
               -  No clinically significant pleural or peritoneal effusion requiring drainage.&#xD;
&#xD;
        For birinapant combination cohorts only:&#xD;
&#xD;
          -  ANC ≥ 1500/μL.&#xD;
&#xD;
        For venetoclax combination cohorts only:&#xD;
&#xD;
          -  Documented diagnosis of CLL that meets the International Workshop on Chronic&#xD;
             Lymphocytic Leukemia (IWCLL) criteria&#xD;
&#xD;
          -  Measurable nodal disease by computed tomography (CT) for SLL&#xD;
&#xD;
          -  Relapsed/refractory disease with an indication for treatment&#xD;
&#xD;
          -  Adequate marrow function independent of growth factor or transfusion support within 2&#xD;
             weeks of screening as follows, unless cytopenia is due to marrow involvement of CLL&#xD;
             Platelet counts ≥ 75,000/μL For those patients with a screening lymphocyte count &lt;&#xD;
             5,000 cells/μL, historical data confirming a lymphocyte count 5,000 cells/μL at time&#xD;
             of diagnosis is required&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior DR5 agonist therapy.&#xD;
&#xD;
          -  Prior Bcl-family inhibitor therapy&#xD;
&#xD;
          -  Known clinically significant history of liver disease including Child-Pugh Class B or&#xD;
             C, including active viral or other hepatitis (e.g., hepatitis B or hepatitis C virus),&#xD;
             current alcohol abuse, non-alcoholic steatohepatitis (NASH), or cirrhosis.&#xD;
&#xD;
          -  Diagnosis of any secondary malignancy within 3 years prior to enrollment&#xD;
&#xD;
          -  Untreated or active central nervous system (CNS) metastases (progressing or requiring&#xD;
             anticonvulsants or corticosteroids for symptomatic control).&#xD;
&#xD;
          -  Current Grade &gt; 1 toxicity (except alopecia and anorexia) from prior therapy. Patients&#xD;
             with current Grade 2 chronic toxicities that are well-controlled by medications may be&#xD;
             enrolled after discussion with medical monitor.&#xD;
&#xD;
          -  For birinapant-containing combination cohort only:&#xD;
&#xD;
               -  Patients who have previously received birinapant treatment&#xD;
&#xD;
               -  History of allergic reactions attributed to compounds of similar chemical or&#xD;
                  biologic composition to birinapant&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Requires concomitant chronic use of anti-tumor necrosis factor (anti-TNF) therapies&#xD;
             (e.g. infliximab, golimumab, certolizumab, adalimumab, etanercept) within 5 half-lives&#xD;
             of drug prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Requires systemic or chronic topical steroids or immunosuppressive therapy within 4&#xD;
             weeks prior to study treatment or anticipated need of systemic corticosteroids or&#xD;
             immunosuppressive therapy during study participation&#xD;
&#xD;
          -  Evidence of active, non-infectious pneumonitis or history of clinically significant&#xD;
             interstitial lung disease&#xD;
&#xD;
          -  Chondrosarcoma Cohort: Mesenchymal, dedifferentiated, and extraskeletal myxoid&#xD;
             chondrosarcoma subtypes&#xD;
&#xD;
          -  For venetoclax-containing combination cohort only:&#xD;
&#xD;
               -  Transformation of CLL to aggressive NHL (Richter's transformation or&#xD;
                  pro-lymphocytic leukemia, or DLBCL or CNS involvement by CLL&#xD;
&#xD;
               -  Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia&#xD;
&#xD;
               -  History of confirmed progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Hypersensitivity to venetoclax or to any of the excipients&#xD;
&#xD;
          -  Malabsorption syndrome or other condition that precludes enteral route of&#xD;
             administration&#xD;
&#xD;
          -  Inability to swallow a large number of tablets&#xD;
&#xD;
          -  Treatment with any other anti-cancer agent, investigational or otherwise) within 4&#xD;
             weeks or five half-lives of the drug, whichever is shorter, prior to first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Patients who have received the following agents:&#xD;
&#xD;
               -  Strong and moderate CYP3A inhibitors (Appendix 12) within 7 days prior to the&#xD;
                  first dose of study drug administration&#xD;
&#xD;
               -  Strong and moderate CYP3A inducers (Appendix 12) within days prior to the first&#xD;
                  dose of study drug administration&#xD;
&#xD;
               -  Consumed grapefruit, grapefruit juice, Seville oranges (including marmalade&#xD;
                  containing Seville oranges), Seville orange juice, or star fruit within 3 days&#xD;
                  prior to the first dose of study drug and throughout venetoclax administration&#xD;
&#xD;
          -  Vaccination with a live vaccine within 28 days prior to study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Humke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IGM Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>650 265 6428</phone>
    <email>clinicaltrials@igmbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI at Healthone</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials</last_name>
      <email>clinicaltrials@igmbio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed and/or Refractory</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Advanced Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

